title: Efalizumab for subacute cutaneous lupus: report of two different outcomes.
authors.forename: D
authors.initials: D
authors.lastname: Sánchez-Cano
authors.forename: J L
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: R
authors.initials: R
authors.lastname: Ríos-Fernández
authors.forename: M T
authors.initials: MT
authors.lastname: Gutiérrez-Salmerón
authors.forename: M A
authors.initials: MA
authors.lastname: Fernández Pugnaire
authors.forename: N
authors.initials: N
authors.lastname: Ortego-Centeno
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab